Nano-X
Based on scientific research from the Principal Investigator, Sine Hadrup who is a Professor and Head of Section at the Department of Health Technology at Technical University of Denmark (DTU), the project has the ambition to create a novel solution for in-vivo engineering of T cells. The Nano-X solution can deliver any gene, mRNA or protein, and combinations hereof to T cells. Thereby offering a versatile and flexible platform to solve future challenges for in-vivo drug delivery and in vivo engineering of immune cells.
Project summary
Purpose
To create a novel solution for in-vivo engineering of T cells allowing the delivery any gene, mRNA or protein, and combinations thereof, to T cells.
Host university
Technical University of Denmark
Funding per year
DKK 6,5M
Duration
Three years
Expected outcome
Viable startup that can raise seed or Series A financing
Project leaders
See who heads the Nano-X project on its mission to create a novel solution for in-vivo engineering of T cells allowing the delivery any gene, mRNA or protein, and combinations thereof, to T cells.
“At Nano-X, we aim at advancing our polymeric nanoparticle technology that can optimize today’s T-cell therapies along with enabling next-generation in vivo-generated CAR-T cells which can transform cell therapy into a cost-efficient, scalable, and truly off-the-shelf solution for patients”
Kåre Engkilde
Entrepreneur in Residence